The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer
December 12th 2019Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.
Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer
December 12th 2019Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
December 12th 2019Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer
November 15th 2019The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.
Margetuximab Elicits Modest Survival Extension in HER2+ Breast Cancer
October 24th 2019The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy.
Tucatinib Triplet Improves Survival in Advanced HER2+ Breast Cancer
October 21st 2019Tucatinib combined with trastuzumab and capecitabine improved overall survival and progression-free survival compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer.
Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases
October 17th 2019Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.
Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer
October 16th 2019Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.
Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer
October 14th 2019Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.
Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases
October 8th 2019Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.
Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer
As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.
Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer
Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.
Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management
September 19th 2019Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.
Fixed-Dose Subcutaneous Pertuzumab Combo Shows Noninferiority in HER2+ Breast Cancer
September 13th 2019A fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy demonstrated noninferior pharmacokinetics compared with the standard IV infusions of the regimen in patients with HER2-positive early breast cancer, meeting the primary endpoint of the phase III FeDeriCa trial (NCT03493854).